ON-DEMAND ROUNDTABLE
From Bench to Bedside: Advancing MRD Detection with Cutting-Edge NGS Tools
About the roundtable
Join us and four industry experts as we discuss advancements in next generation sequencing (NGS) tools and how they can accelerate oncology research.
Discussion topics:
- How ultra-sensitive next-generation sequencing (NGS) can help detect minimal residual disease (MRD)
- How researchers are optimizing downstream analysis for oncology samples
- Pros and cons of various panels, including whole genome, whole exome, and targeted panels, as a standard of care for different types of cancer
Unable to attend live? Register today and we’ll send the recording to watch at your convenience.
Meet our panelists
T. Grant Belgard, Ph.D.
CEO, The Bioinformatics CRO
Read Bio
Dr. T. Grant Belgard founded The Bioinformatics CRO, a global computational biology services provider, in 2018. He is also senior director of bioinformatics at bit.bio and co-founder of clock.bio. Dr. Grant received his doctorate from Oxford with joint training at NIH as a Marshall Scholar and did postdoctoral work at UCLA and Oxford before working as a scientist in biotech, earning an Executive MBA, and becoming an entrepreneur.
Alexa Woodward, Ph.D.
Partnerships and Strategy Manager, Optum
Read Bio
Dr. Alexa Woodward is a genetic epidemiologist with expertise in real-world data and evidence in oncology and beyond. She currently leads data strategy and partnerships for Optum Clinicogenomics. Her previous research interests focused on developing rule-based algorithms for addressing heterogeneity in genetic data.
Jeff Tio, Ph.D.
Director, Integrated Solutions, Azenta Life Sciences
Read Bio
Dr. Jeff Tio has over five years of experience with multiomics technologies. At Azenta, he guides the Technical Support team in providing and designing comprehensive solutions tailored to meet researchers’ project goals. Dr. Tio earned his Ph.D. from Thomas Jefferson University at Philadelphia in biochemistry and a B.S. in biochemistry from Villanova University. He completed his postdoctoral training at an NGS biotechnology company, where he focused his work on R&D (optimization and testing) of NGS platforms.
Elizabeth Louie, Ph.D.
Manager, Technical Applications, Azenta Life Sciences
Read Bio
Dr. Liz Louie joined Azenta in 2011, overseeing gene synthesis and molecular genetics projects while supporting the Project Management team with customer-facing project design and execution. Later, she led the expansion and management of molecular biology and oligo synthesis operations at the Azenta genomics facility in Boston, MA. She currently provides consultative and project design support for researchers and investigators, focusing on genomics, transcriptomics, and proteomics solutions. Her expertise includes next generation sequencing (NGS), DNA and RNA synthesis, genotyping methods, and cell and gene editing workflows. Dr. Liz Louie earned her Ph.D. in molecular and cellular pharmacology from Stony Brook University.
Andrea O’Hara, Ph.D. [Moderator]
Manager, Technical Applications, Azenta Life Sciences
Read Bio
With over a decade of experience with multiomics technologies, Dr. Andrea O’Hara guides technological innovations and life-cycle management at Azenta. She earned her Ph.D. from the University of North Carolina at Chapel Hill in genetics and molecular biology and a B.A. in biology from The John Hopkins University. Dr. O’Hara completed her postdoctoral training at the National Institutes of Health, focusing on genomic alterations in various endometrial cancers.